🟢 Rocket Pharmaceuticals is trading 6.4% up in pre-market with no clear catalyst identified

Rocket Pharmaceuticals is trading 6.4% up in pre-market at $2.76, versus the September 29 close of $2.59.

• No company announcement or other clearly linked catalyst was found for September 30; broad-market indicators are only modestly higher.
• Its latest notable company news was FDA alignment on its Danon disease trial, announced September 15.
• Recent FDA-related analyst coverage dates to September 16 and does not clearly explain this morning’s rise.